BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.
Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics. During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology. Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.
Zacharon Pharmaceuticals is leveraging unique glycobiology expertise to develop an entirely new class of human therapeutics targeting glycans. Zacharon was incorporated in 2004 and has received initial funding through NIH grants and individual investors. Series A financing was more recently provided by Avalon Ventures, a long-standing San Diego-based venture capital firm with a focus on early stage life science companies. With this strong financial backing and innovative drug development platform in place, Zacharon is developing an entirely new class of human therapeutics addressing substantial unmet needs.
ZyStor Therapeutics, Inc. is a privately-held biotechnology company developing enzyme replacement therapies for the treatment of lysosomal storage diseases.
LEAD Therapeutics, Inc. is a chemistry-driven drug discovery company focused on delivering novel and differentiated small molecule IND candidates against clinically validated therapeutic targets, focused primarily on the treatment of Cancer and infectious diseases.
Huxley Pharmaceuticals
Acquisition in 2009
Huxley Pharmaceuticals is private life sciences company founded and managed by Aceras BioMedical, LLC. Aceras is dedicated to funding and developing novel innovations that address unmet medical needs.
Glyko Biomedical
Acquisition in 2002
Glyko Biomedical Ltd. offers scientific research services aimed at developing novel analytic research instrumentation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.